Récepteur cannabinoïde de type CB2 : Questions médicales fréquentes
Nom anglais: Receptor, Cannabinoid, CB2
Descriptor UI:D043885
Tree Number:D12.776.543.750.695.125.200
Termes MeSH sélectionnés :
Databases, Factual
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Récepteur cannabinoïde de type CB2 : Questions médicales les plus fréquentes",
"headline": "Récepteur cannabinoïde de type CB2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Récepteur cannabinoïde de type CB2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-23",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Récepteur cannabinoïde de type CB2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Récepteurs de cannabinoïdes",
"url": "https://questionsmedicales.fr/mesh/D043882",
"about": {
"@type": "MedicalCondition",
"name": "Récepteurs de cannabinoïdes",
"code": {
"@type": "MedicalCode",
"code": "D043882",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.695.125"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Récepteur cannabinoïde de type CB2",
"alternateName": "Receptor, Cannabinoid, CB2",
"code": {
"@type": "MedicalCode",
"code": "D043885",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Emmanuel S Onaivi",
"url": "https://questionsmedicales.fr/author/Emmanuel%20S%20Onaivi",
"affiliation": {
"@type": "Organization",
"name": "Department of Biology, William Paterson University, Wayne, NJ 07470, USA."
}
},
{
"@type": "Person",
"name": "Alexandros Makriyannis",
"url": "https://questionsmedicales.fr/author/Alexandros%20Makriyannis",
"affiliation": {
"@type": "Organization",
"name": "Center for Drug Discovery, Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA; Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA."
}
},
{
"@type": "Person",
"name": "Qing-Rong Liu",
"url": "https://questionsmedicales.fr/author/Qing-Rong%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States."
}
},
{
"@type": "Person",
"name": "Francesca Gado",
"url": "https://questionsmedicales.fr/author/Francesca%20Gado",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy."
}
},
{
"@type": "Person",
"name": "Clementina Manera",
"url": "https://questionsmedicales.fr/author/Clementina%20Manera",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study.",
"datePublished": "2023-04-04",
"url": "https://questionsmedicales.fr/article/37034358",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.eclinm.2023.101932"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association Between Changes in Alcohol Consumption Before and After the Great East Japan Earthquake and Risk of Hypertension: A Study Using the Ministry of Health, Labour and Welfare National Database.",
"datePublished": "2023-03-31",
"url": "https://questionsmedicales.fr/article/36503902",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2188/jea.JE20220161"
}
},
{
"@type": "ScholarlyArticle",
"name": "Machine learning prediction models and nomogram to predict the risk of in-hospital death for severe DKA: A clinical study based on MIMIC-IV, eICU databases, and a college hospital ICU.",
"datePublished": "2023-03-27",
"url": "https://questionsmedicales.fr/article/37001474",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijmedinf.2023.105049"
}
},
{
"@type": "ScholarlyArticle",
"name": "Linking Patterns of Intraoperative Neuromonitoring (IONM) Alerts to the Odds of a New Postoperative Neurological Deficit: Analysis of 27,808 Cervical Spine Procedures From a National Multi-institutional Database.",
"datePublished": "2023-03-24",
"url": "https://questionsmedicales.fr/article/36959181",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/BSD.0000000000001445"
}
},
{
"@type": "ScholarlyArticle",
"name": "Trends in clinical characteristics and outcomes of all critically ill COVID-19 adult patients hospitalized in France between March 2020 and June 2021: a national database study.",
"datePublished": "2023-01-12",
"url": "https://questionsmedicales.fr/article/36631602",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13613-022-01097-3"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Récepteurs de surface cellulaire",
"item": "https://questionsmedicales.fr/mesh/D011956"
},
{
"@type": "ListItem",
"position": 6,
"name": "Récepteurs couplés aux protéines G",
"item": "https://questionsmedicales.fr/mesh/D043562"
},
{
"@type": "ListItem",
"position": 7,
"name": "Récepteurs de cannabinoïdes",
"item": "https://questionsmedicales.fr/mesh/D043882"
},
{
"@type": "ListItem",
"position": 8,
"name": "Récepteur cannabinoïde de type CB2",
"item": "https://questionsmedicales.fr/mesh/D043885"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Récepteur cannabinoïde de type CB2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Récepteur cannabinoïde de type CB2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Récepteur cannabinoïde de type CB2",
"description": "Comment diagnostiquer une dysfonction des récepteurs CB2 ?\nQuels tests sont utilisés pour évaluer les récepteurs CB2 ?\nLes imageries sont-elles utiles pour les récepteurs CB2 ?\nPeut-on mesurer l'activité des récepteurs CB2 ?\nQuels symptômes peuvent indiquer un problème avec les récepteurs CB2 ?",
"url": "https://questionsmedicales.fr/mesh/D043885?mesh_terms=Databases,+Factual&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Récepteur cannabinoïde de type CB2",
"description": "Quels symptômes sont liés à l'activation des récepteurs CB2 ?\nLes récepteurs CB2 affectent-ils l'humeur ?\nQuels troubles sont associés aux récepteurs CB2 ?\nLes récepteurs CB2 jouent-ils un rôle dans l'anxiété ?\nPeut-on ressentir des effets secondaires avec les récepteurs CB2 ?",
"url": "https://questionsmedicales.fr/mesh/D043885?mesh_terms=Databases,+Factual&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Récepteur cannabinoïde de type CB2",
"description": "Peut-on prévenir les troubles liés aux récepteurs CB2 ?\nY a-t-il des habitudes à éviter pour protéger les récepteurs CB2 ?\nL'exercice physique influence-t-il les récepteurs CB2 ?\nLe stress a-t-il un impact sur les récepteurs CB2 ?\nLes suppléments peuvent-ils aider les récepteurs CB2 ?",
"url": "https://questionsmedicales.fr/mesh/D043885?mesh_terms=Databases,+Factual&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Récepteur cannabinoïde de type CB2",
"description": "Quels traitements ciblent les récepteurs CB2 ?\nLes cannabinoïdes sont-ils efficaces pour la douleur ?\nY a-t-il des traitements non médicamenteux pour les récepteurs CB2 ?\nLes traitements à base de cannabis sont-ils sûrs ?\nComment les traitements affectent-ils le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D043885?mesh_terms=Databases,+Factual&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Récepteur cannabinoïde de type CB2",
"description": "Quelles complications peuvent survenir avec les récepteurs CB2 ?\nLes récepteurs CB2 sont-ils liés à des maladies graves ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?\nLes complications des récepteurs CB2 peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D043885?mesh_terms=Databases,+Factual&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Récepteur cannabinoïde de type CB2",
"description": "Quels sont les facteurs de risque pour les troubles des récepteurs CB2 ?\nLe tabagisme est-il un facteur de risque pour les récepteurs CB2 ?\nL'alimentation influence-t-elle les récepteurs CB2 ?\nLe stress est-il un facteur de risque pour les récepteurs CB2 ?\nLes maladies auto-immunes augmentent-elles les risques ?",
"url": "https://questionsmedicales.fr/mesh/D043885?mesh_terms=Databases,+Factual&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des récepteurs CB2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests biologiques et l'évaluation des symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les récepteurs CB2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'immunohistochimie et des analyses génétiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les imageries sont-elles utiles pour les récepteurs CB2 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les techniques d'imagerie ne ciblent pas spécifiquement les récepteurs CB2."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité des récepteurs CB2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des méthodes biochimiques permettent d'évaluer l'activité des récepteurs CB2."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les récepteurs CB2 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs chroniques et des troubles immunitaires peuvent signaler un problème."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à l'activation des récepteurs CB2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activation des récepteurs CB2 peut réduire l'inflammation et la douleur."
}
},
{
"@type": "Question",
"name": "Les récepteurs CB2 affectent-ils l'humeur ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer l'humeur en modulant la réponse au stress."
}
},
{
"@type": "Question",
"name": "Quels troubles sont associés aux récepteurs CB2 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles comme l'arthrite et la sclérose en plaques sont associés aux CB2."
}
},
{
"@type": "Question",
"name": "Les récepteurs CB2 jouent-ils un rôle dans l'anxiété ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur activation peut avoir un effet anxiolytique dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Peut-on ressentir des effets secondaires avec les récepteurs CB2 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont rares, mais peuvent inclure des changements d'humeur."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux récepteurs CB2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un mode de vie actif peuvent aider à prévenir certains troubles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter pour protéger les récepteurs CB2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabac et l'alcool peut protéger la fonction des récepteurs CB2."
}
},
{
"@type": "Question",
"name": "L'exercice physique influence-t-il les récepteurs CB2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la fonction des récepteurs CB2."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur les récepteurs CB2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut altérer la fonction des récepteurs CB2."
}
},
{
"@type": "Question",
"name": "Les suppléments peuvent-ils aider les récepteurs CB2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains suppléments, comme les oméga-3, peuvent soutenir la fonction des récepteurs CB2."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les récepteurs CB2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments cannabinoïdes et des anti-inflammatoires ciblent les récepteurs CB2."
}
},
{
"@type": "Question",
"name": "Les cannabinoïdes sont-ils efficaces pour la douleur ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cannabinoïdes peuvent réduire la douleur en agissant sur les récepteurs CB2."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux pour les récepteurs CB2 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies physiques et des approches comportementales peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Les traitements à base de cannabis sont-ils sûrs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement sûrs, mais nécessitent une supervision médicale."
}
},
{
"@type": "Question",
"name": "Comment les traitements affectent-ils le système immunitaire ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent moduler la réponse immunitaire via les récepteurs CB2."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les récepteurs CB2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme l'inflammation chronique et la douleur persistante peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les récepteurs CB2 sont-ils liés à des maladies graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le cancer et les maladies auto-immunes peuvent être liées."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en augmentant la douleur et l'inconfort."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées ou réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Les complications des récepteurs CB2 peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical régulier peut aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles des récepteurs CB2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le mode de vie et des antécédents familiaux de maladies."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque pour les récepteurs CB2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer la fonction des récepteurs CB2 et augmenter les risques."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les récepteurs CB2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en acides gras oméga-3 peut soutenir leur fonction."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque pour les récepteurs CB2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter négativement la fonction des récepteurs CB2."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes augmentent-elles les risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes de maladies auto-immunes peuvent avoir des risques accrus."
}
}
]
}
]
}
Adverse events of special interest (AESIs) were pre-specified to be monitored for the COVID-19 vaccines. Some AESIs are not only associated with the vaccines, but with COVID-19. Our aim was to charact...
A multi-national cohort study with data from primary care, electronic health records, and insurance claims mapped to a common data model. This study's evidence was collected between Jan 1, 2017 and th...
Substantial heterogeneity by age was seen for AESI rates, with some clearly increasing with age but others following the opposite trend. Similarly, differences were also observed across databases for ...
Our findings suggest all AESIs are more common after COVID-19 than in the general population. Thromboembolic events were particularly common, and over 10-fold more so. More research is needed to conte...
None....
The 2011 Great East Japan Earthquake has resulted in a nuclear accident, forcing residents of the surrounding areas to evacuate. To determine any association between excessive drinking and hypertensio...
This retrospective study assessed data from the Japanese National Database. Cumulative population data for Fukushima Prefecture (3,497,576 people) were analyzed by categorizing residents into four are...
The proportion of excessive drinkers among women increased after the disaster in all areas examined. The association between excessive drinking and the incidence of hypertension was determined among m...
Excessive drinking post-disaster may be associated with an increased risk of hypertension among men and women, especially among women in the evacuation areas....
To establish a prediction model and assess the risk factors for severe diabetic ketoacidosis (DKA) in adult patients during the ICU....
With DKA hospitalization rates consistently increasing, in-hospital mortality has become a growing concern....
DKA patients aged >18 years old in the US-based critical care database (Medical Information Mart for Intensive Care (MIMIC-IV)) were considered. Independent risk factors for in-hospital mortality were...
A multivariable model that included acute physiology score III (APS III), the highest levels of blood plasma osmolality (osmolarity_max), minimum osmolarity (osmolarity_min)/osmolarity _max, vasopress...
The predictive XGB and nomogram models for predicting in-hospital patient deaths with DKA were effective. The forecast models can help clinical physicians promptly identify patients at high risk of DK...
Retrospective review of a national multi-institutional database of 27,808 extradural cervical spine procedures performed between January 2017 and May 2021....
Characterize intraoperative neuromonitoring alerts by the patterns of modalities and nerves/muscles involved and quantify risk of new-onset neurological deficit for patients with a primary diagnosis o...
Phenotyping alert patterns and linking those patterns with risk is needed to facilitate clinical decision-making....
Cases with alerts were categorized by patterns of modalities or nerves/muscles involved, and alert status at closure. Unadjusted odds ratios (ORs) for new-onset neurological deficit were calculated. A...
There was significantly increased risk of a new neurological deficit for procedures involving posterior compared with anterior approaches (OR: 1.82, P=0.001) and procedures involving three levels comp...
Risk elevation and risk mitigation after an intraoperative neuromonitoring alert during surgery is dependent on the type and pattern of alert....
Studies regarding coronavirus disease 2019 (COVID-19) were mainly performed in the initial wave, but some small-scale data points to prognostic differences for patients in successive waves. We therefo...
We performed a national retrospective cohort study, including all adult patients hospitalized in French ICUs from March 1, 2020 to June 30, 2021, and identified three surge periods. Primary and second...
105,979 critically ill ICU-admitted COVID-19 patients were allocated to the relevant three surge periods. In-hospital mortality for surges 1, 2, and 3 was, respectively, 24%, 27%, and 24%. Invasive me...
In this large database of ICU patients admitted for COVID-19, we observed a decline in invasive mechanical ventilation, vasopressors, and RRT use over time but a high risk of in-hospital death. Vaccin...
Clinical trials have demonstrated higher complete response rates in the immuno-oncology-based combination arms than in the tyrosine kinase inhibitor arms in patients with metastatic renal cell carcino...
Using the International Metastatic Renal Cell Carcinoma Database Consortium, response-evaluable patients who received frontline immuno-oncology-based combination therapy or tyrosine kinase inhibitor m...
A total of 52 (4.6%) of 1,126 and 223 (3.0%) of 7,557 patients experienced complete response to immuno-oncology-based and tyrosine kinase inhibitor therapies, respectively (...
The complete response rate was not as high in the real-world population as in the clinical trial population. Among those who experienced complete response, several adverse clinicopathological features...
Clinical assessment of T and N stages in rectal cancer is important to guide decision-making. The present study aimed to assess the accuracy of the clinical T and N staging of rectal cancer compared t...
This retrospective study used data from the National Cancer Database (NCDB) between 2004 and 2017. Patients with non-metastatic rectal adenocarcinoma who did not receive neoadjuvant therapy were revie...
The study included 8929 patients (57.3% male) with a mean age of 64 years. Clinical T stage and N stage were identical to pathologic stages in 70.3% and 77.6% of patients, respectively. Sensitivity an...
There was a moderate agreement between the clinical and pathologic T stages and a fair agreement between the clinical and pathologic N stages. The clinical assessment of the N stage was highly specifi...
(1) Background: The aging population poses challenges for hospital systems. Aortic stenosis is among the most frequent diseases in very old patients. The aim of this study was to describe gender and a...
Chronic Obstructive Pulmonary Disease (COPD) is associated with significant mortality and well-defined aetiological factors. Previous reports indicate that mortality from COPD is falling worldwide. Th...
We extracted COPD data from the Global Burden of Disease database based on the International Classification of Diseases versions 10 (J41, 42, 43, 44 and 47). Age-standardised prevalence rates (ASPRs),...
In 2019, the median ASPR across Europe was 3230/100,000 for males and 2202/100,000 for females. Between 2001 and 2019, the median percentage change in ASPR was - 9.7% for males and 4.3% for females. 2...
In the EU between 2001 and 2019 COPD prevalence has overall increased in females but continues to decrease in males and in some countries, female prevalence now exceeds that of males. COPD mortality i...
Adjuvant medical treatment to reduce the recurrence rate after burr hole surgery for chronic subdural hematoma (CSDH) has not yet been established. This study aimed to investigate the association betw...
This observational study used the Japanese Diagnostic Procedure Combination inpatient database, a nationwide inpatient database in Japan, from July 1, 2010, to March 31, 2019. The authors identified p...
Of the 149,543 patients with CSDH treated at 1100 hospitals, 7366 (4.9%) were TXA users. Propensity score matching created 6564 matched pairs with highly balanced baseline characteristics. The reopera...
Findings of this study, using a nationwide inpatient database, suggest that adjuvant TXA use after burr hole surgery was associated with a reduced reoperation rate in patients with CSDH....
